Pharmacovigilance and Drug Safety Software Market by Functionality (Adverse Event Reporting, Fully Integrated Software), Delivery Mode (On-premise, On-demand/Cloud based (SAAS)), End-user (Pharma & Biotech Companies, CROs, BPOs) - Global Forecast to 2019
The global pharmacovigilance and drug safety software market is expected to grow at a CAGR of 6.5% from 2014 to 2019. North America region held the largest share of the pharmacovigilance and drug safety software market in 2014. However, Asian and Latin American countries symbolize high growth markets. This is owing to a rise in research outsourcing by pharmaceutical giants and growing public and private investments in pharmaceutical R&D in these emerging nations.
The growth of the global pharmacovigilance and drug safety software market is mainly driven by increasing incidence rates of adverse drug reactions (ADRs), growing adoption of pharmacovigilance software by outsourcing companies (such as CROs and BPOs), and huge pressure on pharma companies to develop novel and safe drugs. However, the dearth of standard regulations and lack of pharmacovigilance professionals are some of the key factors restraining the growth of this market.
In this report, the global pharmacovigilance and drug safety software market has been classified into four segments on the basis of functionality, namely, adverse event reporting software, drug safety audits software, issue tracking software, and fully integrated software. The global pharmacovigilance and drug safety software market is segmented into two segments on the basis of delivery mode, namely, on-premise delivery mode and on-demand/cloud based (SaaS) delivery mode. The global pharmacovigilance and drug safety software market is also segmented on the basis of end users including pharma and biotech companies, contract research organizations (CROs), business process outsourcing (BPO) firms, and other pharmacovigilance service providers.
The global pharmacovigilance and drug safety software market comprises large number of small and mid-size software developers and service providers. As of 2014, the global pharmacovigilance and drug safety software market was dominated by Oracle Corporation (U.S.).
New service launches; agreements, and partnerships; software developments; and geographical expansions are some of the major strategies adopted by most of the market players to achieve growth in the pharmacovigilance and drug safety software market.
Reasons to Buy the Report:
From an insight perspective, this research report focuses on various levels of analysis —industry analysis (value chain analysis and Porter’s five force model), market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the pharmacovigilance and drug safety software market, high-growth regions and their respective drivers, restraints, challenges, and opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help them to garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned four strategies (market penetration, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
The growth of the global pharmacovigilance and drug safety software market is mainly driven by increasing incidence rates of adverse drug reactions (ADRs), growing adoption of pharmacovigilance software by outsourcing companies (such as CROs and BPOs), and huge pressure on pharma companies to develop novel and safe drugs. However, the dearth of standard regulations and lack of pharmacovigilance professionals are some of the key factors restraining the growth of this market.
In this report, the global pharmacovigilance and drug safety software market has been classified into four segments on the basis of functionality, namely, adverse event reporting software, drug safety audits software, issue tracking software, and fully integrated software. The global pharmacovigilance and drug safety software market is segmented into two segments on the basis of delivery mode, namely, on-premise delivery mode and on-demand/cloud based (SaaS) delivery mode. The global pharmacovigilance and drug safety software market is also segmented on the basis of end users including pharma and biotech companies, contract research organizations (CROs), business process outsourcing (BPO) firms, and other pharmacovigilance service providers.
The global pharmacovigilance and drug safety software market comprises large number of small and mid-size software developers and service providers. As of 2014, the global pharmacovigilance and drug safety software market was dominated by Oracle Corporation (U.S.).
New service launches; agreements, and partnerships; software developments; and geographical expansions are some of the major strategies adopted by most of the market players to achieve growth in the pharmacovigilance and drug safety software market.
Reasons to Buy the Report:
From an insight perspective, this research report focuses on various levels of analysis —industry analysis (value chain analysis and Porter’s five force model), market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the pharmacovigilance and drug safety software market, high-growth regions and their respective drivers, restraints, challenges, and opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help them to garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned four strategies (market penetration, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on pharmacovigilance and drug safety software offered by the top 10 players in the pharmacovigilance and drug safety software market. The report analyzes the pharmacovigilance and drug safety software market on the basis of functionality, delivery mode, end user, and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various pharmacovigilance and drug safety software across geographies.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the pharmacovigilance and drug safety software market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the pharmacovigilance and drug safety software market.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
4.2 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
4.3 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
4.4 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
5.2.1 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
5.2.2 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE
5.2.3 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
5.3 MARKET DYNAMICS
5.3.1 KEY MARKET DRIVERS
5.3.1.1 Intensification of drug safety regulations by government authorities
5.3.1.2 Heavy clinical R&D expenditure by the pharmaceutical industry
5.3.1.3 Benefits offered by PV solutions—reduced cost and time involved in clinical trial processes
5.3.1.4 Government grants to support clinical trials
5.3.1.5 Large investments in healthcare IT by governments from mature as well as developing nations
5.3.2 KEY MARKET RESTRAINTS
5.3.2.1 Dearth of healthcare IT professionals
5.3.2.2 Cultural differences and language barriers
5.3.3 KEY MARKET OPPORTUNITIES
5.3.3.1 Cloud technology provides opportunities for industry players
5.3.3.2 Emerging markets to offer high growth opportunities
5.3.4 KEY MARKET CHALLENGES
5.3.4.1 Lack of standardization and harmonization of drug safety regulations
5.3.4.2 Low adoption of pharmacovigilance solutions in the least developed countries
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 PORTER’S FIVE FORCES ANALYSIS
6.2.1 THREAT FROM NEW ENTRANTS
6.2.2 THREAT FROM SUBSTITUTES
6.2.3 BARGAINING POWER OF SUPPLIERS
6.2.4 BARGAINING POWER OF BUYERS
6.2.5 INTENSITY OF COMPETITIVE RIVALRY
6.3 INDUSTRY TRENDS
6.3.1 STRONG FOCUS ON NEW PRODUCT LAUNCHES
6.3.2 GROWING MARKET PREFERENCE FOR CLOUD-BASED PLATFORMS
7 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
7.1 INTRODUCTION
7.2 ADVERSE EVENT REPORTING SOFTWARE
7.3 DRUG SAFETY AUDIT SOFTWARE
7.4 FULLY INTEGRATED SOFTWARE
7.5 ISSUE TRACKING SOFTWARE
8 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE
8.1 INTRODUCTION
8.2 ON-PREMISE DELIVERY MODE
8.3 ON-DEMAND/CLOUD-BASED (SAAS) DELIVERY MODE
9 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
9.1 INTRODUCTION
9.2 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.3 PHARMA AND BIOTECH COMPANIES
9.4 BUSINESS PROCESS OUTSOURCING (BPO) FIRMS
9.5 OTHER PHARMACOVIGILANCE SERVICE PROVIDERS
10 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 U.K.
10.3.3 FRANCE
10.3.4 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REST OF ASIA-PACIFIC
10.5 ROW (REST OF THE WORLD)
10.5.1 LATIN AMERICA
10.5.2 MIDDLE EAST
10.5.3 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
11.3 COMPETITIVE SITUATION AND TRENDS
11.4 RECENT DEVELOPMENTS
11.4.1 NEW PRODUCT LAUNCHES
11.4.2 ACQUISITIONS, PARTNERSHIPS, AND AGREEMENTS
11.4.3 NEW SERVICE LAUNCHES AND SERVICE EXPANSIONS
11.4.4 GEOGRAPHICAL EXPANSIONS
11.4.5 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 INTRODUCTION
12.2 ORACLE CORPORATION
12.2.1 BUSINESS OVERVIEW
12.2.2 PRODUCT PORTFOLIO
12.2.3 KEY STRATEGY
12.2.4 RECENT DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.3 ARISGLOBAL LLC
12.3.1 BUSINESS OVERVIEW
12.3.2 PRODUCTS & SERVICES
12.3.3 KEY STRATEGY
12.3.4 RECENT DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.4 EXTEDO GMBH
12.4.1 BUSINESS OVERVIEW
12.4.2 PRODUCTS & SERVICES
12.4.3 KEY STRATEGY
12.4.4 SWOT ANALYSIS
12.5 AB-CUBE
12.5.1 BUSINESS OVERVIEW
12.5.2 PRODUCT & SERVICES
12.5.3 KEY STRATEGY
12.6 ENNOV SOLUTIONS, INC.
12.6.1 BUSINESS OVERVIEW
12.6.2 PRODUCTS & SERVICES
12.6.3 KEY STRATEGY
12.6.4 RECENT DEVELOPMENTS
12.7 ONLINE BUSINESS APPLICATIONS, INC.
12.7.1 BUSINESS OVERVIEW
12.7.2 PRODUCTS & SERVICES
12.7.3 KEY STRATEGY
12.7.4 RECENT DEVELOPMENTS
12.8 SARJEN SYSTEMS PVT. LTD.
12.8.1 BUSINESS OVERVIEW
12.8.2 PRODUCTS & SERVICES
12.8.3 KEY STRATEGY
12.9 SPARTA SYSTEMS, INC.
12.9.1 BUSINESS OVERVIEW
12.9.2 PRODUCTS & SERVICES
12.9.3 KEY STRATEGY
12.9.4 RECENT DEVELOPMENTS
12.10 UMBRA GLOBAL, LLC
12.10.1 BUSINESS OVERVIEW
12.10.2 PRODUCTS & SERVICES
12.10.3 KEY STRATEGY
12.10.4 RECENT DEVELOPMENTS
12.11 UNITED BIOSOURCE CORPORATION (AN EXPRESS SCRIPTS COMPANY)
12.11.1 BUSINESS OVERVIEW
12.11.2 SERVICES PORTFOLIO
12.11.3 KEY STRATEGY
12.11.4 RECENT DEVELOPMENTS
13 APPENDIX
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
4.2 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
4.3 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
4.4 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
5.2.1 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
5.2.2 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE
5.2.3 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
5.3 MARKET DYNAMICS
5.3.1 KEY MARKET DRIVERS
5.3.1.1 Intensification of drug safety regulations by government authorities
5.3.1.2 Heavy clinical R&D expenditure by the pharmaceutical industry
5.3.1.3 Benefits offered by PV solutions—reduced cost and time involved in clinical trial processes
5.3.1.4 Government grants to support clinical trials
5.3.1.5 Large investments in healthcare IT by governments from mature as well as developing nations
5.3.2 KEY MARKET RESTRAINTS
5.3.2.1 Dearth of healthcare IT professionals
5.3.2.2 Cultural differences and language barriers
5.3.3 KEY MARKET OPPORTUNITIES
5.3.3.1 Cloud technology provides opportunities for industry players
5.3.3.2 Emerging markets to offer high growth opportunities
5.3.4 KEY MARKET CHALLENGES
5.3.4.1 Lack of standardization and harmonization of drug safety regulations
5.3.4.2 Low adoption of pharmacovigilance solutions in the least developed countries
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 PORTER’S FIVE FORCES ANALYSIS
6.2.1 THREAT FROM NEW ENTRANTS
6.2.2 THREAT FROM SUBSTITUTES
6.2.3 BARGAINING POWER OF SUPPLIERS
6.2.4 BARGAINING POWER OF BUYERS
6.2.5 INTENSITY OF COMPETITIVE RIVALRY
6.3 INDUSTRY TRENDS
6.3.1 STRONG FOCUS ON NEW PRODUCT LAUNCHES
6.3.2 GROWING MARKET PREFERENCE FOR CLOUD-BASED PLATFORMS
7 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
7.1 INTRODUCTION
7.2 ADVERSE EVENT REPORTING SOFTWARE
7.3 DRUG SAFETY AUDIT SOFTWARE
7.4 FULLY INTEGRATED SOFTWARE
7.5 ISSUE TRACKING SOFTWARE
8 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE
8.1 INTRODUCTION
8.2 ON-PREMISE DELIVERY MODE
8.3 ON-DEMAND/CLOUD-BASED (SAAS) DELIVERY MODE
9 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
9.1 INTRODUCTION
9.2 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.3 PHARMA AND BIOTECH COMPANIES
9.4 BUSINESS PROCESS OUTSOURCING (BPO) FIRMS
9.5 OTHER PHARMACOVIGILANCE SERVICE PROVIDERS
10 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 U.K.
10.3.3 FRANCE
10.3.4 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REST OF ASIA-PACIFIC
10.5 ROW (REST OF THE WORLD)
10.5.1 LATIN AMERICA
10.5.2 MIDDLE EAST
10.5.3 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
11.3 COMPETITIVE SITUATION AND TRENDS
11.4 RECENT DEVELOPMENTS
11.4.1 NEW PRODUCT LAUNCHES
11.4.2 ACQUISITIONS, PARTNERSHIPS, AND AGREEMENTS
11.4.3 NEW SERVICE LAUNCHES AND SERVICE EXPANSIONS
11.4.4 GEOGRAPHICAL EXPANSIONS
11.4.5 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 INTRODUCTION
12.2 ORACLE CORPORATION
12.2.1 BUSINESS OVERVIEW
12.2.2 PRODUCT PORTFOLIO
12.2.3 KEY STRATEGY
12.2.4 RECENT DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.3 ARISGLOBAL LLC
12.3.1 BUSINESS OVERVIEW
12.3.2 PRODUCTS & SERVICES
12.3.3 KEY STRATEGY
12.3.4 RECENT DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.4 EXTEDO GMBH
12.4.1 BUSINESS OVERVIEW
12.4.2 PRODUCTS & SERVICES
12.4.3 KEY STRATEGY
12.4.4 SWOT ANALYSIS
12.5 AB-CUBE
12.5.1 BUSINESS OVERVIEW
12.5.2 PRODUCT & SERVICES
12.5.3 KEY STRATEGY
12.6 ENNOV SOLUTIONS, INC.
12.6.1 BUSINESS OVERVIEW
12.6.2 PRODUCTS & SERVICES
12.6.3 KEY STRATEGY
12.6.4 RECENT DEVELOPMENTS
12.7 ONLINE BUSINESS APPLICATIONS, INC.
12.7.1 BUSINESS OVERVIEW
12.7.2 PRODUCTS & SERVICES
12.7.3 KEY STRATEGY
12.7.4 RECENT DEVELOPMENTS
12.8 SARJEN SYSTEMS PVT. LTD.
12.8.1 BUSINESS OVERVIEW
12.8.2 PRODUCTS & SERVICES
12.8.3 KEY STRATEGY
12.9 SPARTA SYSTEMS, INC.
12.9.1 BUSINESS OVERVIEW
12.9.2 PRODUCTS & SERVICES
12.9.3 KEY STRATEGY
12.9.4 RECENT DEVELOPMENTS
12.10 UMBRA GLOBAL, LLC
12.10.1 BUSINESS OVERVIEW
12.10.2 PRODUCTS & SERVICES
12.10.3 KEY STRATEGY
12.10.4 RECENT DEVELOPMENTS
12.11 UNITED BIOSOURCE CORPORATION (AN EXPRESS SCRIPTS COMPANY)
12.11.1 BUSINESS OVERVIEW
12.11.2 SERVICES PORTFOLIO
12.11.3 KEY STRATEGY
12.11.4 RECENT DEVELOPMENTS
13 APPENDIX
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
LIST OF TABLES
Table 1 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY, 2012–2019 ($MILLION)
Table 2 ADVERSE EVENT REPORTING SOFTWARE MARKET, BY REGION, 2012–2019 ($MILLION)
Table 3 DRUG SAFETY AUDIT SOFTWARE MARKET, BY REGION, 2012–2019 ($MILLION)
Table 4 FULLY INTEGRATED SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 5 ISSUE TRACKING SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 6 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE 2012–2019 ($MILLION)
Table 7 ON-PREMISE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 8 ON-DEMAND/CLOUD-BASED PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 9 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
Table 10 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2012–2019 ($MILLION)
Table 11 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR PHARMA AND BIOTECH COMPANIES, BY REGION, 2012–2019 ($MILLION)
Table 12 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR BUSINESS PROCESS OUTSOURCING FIRMS, BY REGION, 2012–2019 ($MILLION)
Table 13 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR OTHER SERVICE PROVIDERS, BY REGION, 2012–2019 ($MILLION)
Table 14 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 15 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 16 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 17 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 18 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 19 U.S.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 20 U.S.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 21 U.S.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 22 CANADA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 23 CANADA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 24 CANADA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 25 EUROPE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 26 EUROPE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 27 EUROPEAN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 28 EUROPE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 29 GERMANY: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 30 GERMANY: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 31 GERMANY: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 32 U.K.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 33 U.K.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 34 U.K.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 35 FRANCE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 36 FRANCE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 37 FRANCE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 38 ROE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 39 ROE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 40 ROE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 41 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 42 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 43 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 44 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 45 JAPAN: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 46 JAPAN: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 47 JAPAN: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 48 CHINA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 49 CHINA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 50 CHINA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 51 INDIA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 52 INDIA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 53 INDIA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 54 ROAPAC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 55 ROAPAC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 56 ROAPAC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 57 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 58 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 59 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 60 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 61 LATIN AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 62 LATIN AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 63 LATIN AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 64 MIDDLE EAST: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 65 MIDDLE EAST: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 66 MIDDLE EAST: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 67 AFRICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 68 AFRICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 69 AFRICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 70 TOP 5 NEW PRODUCT LAUNCHES, 2012–2014
Table 71 TOP 5 ACQUISITIONS, PARTNERSHIPS, AND AGREEMENTS, 2012–2014
Table 72 TOP 5 NEW SERVICE LAUNCHES AND SERVICE EXPANSIONS, 2012–2014
Table 73 GEOGRAPHICAL EXPANSIONS, 2012–2014
Table 74 TOP 5 OTHER DEVELOPMENTS, 2012–2014
Table 1 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY, 2012–2019 ($MILLION)
Table 2 ADVERSE EVENT REPORTING SOFTWARE MARKET, BY REGION, 2012–2019 ($MILLION)
Table 3 DRUG SAFETY AUDIT SOFTWARE MARKET, BY REGION, 2012–2019 ($MILLION)
Table 4 FULLY INTEGRATED SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 5 ISSUE TRACKING SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 6 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE 2012–2019 ($MILLION)
Table 7 ON-PREMISE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 8 ON-DEMAND/CLOUD-BASED PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION 2012–2019 ($MILLION)
Table 9 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
Table 10 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2012–2019 ($MILLION)
Table 11 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR PHARMA AND BIOTECH COMPANIES, BY REGION, 2012–2019 ($MILLION)
Table 12 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR BUSINESS PROCESS OUTSOURCING FIRMS, BY REGION, 2012–2019 ($MILLION)
Table 13 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE FOR OTHER SERVICE PROVIDERS, BY REGION, 2012–2019 ($MILLION)
Table 14 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 15 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 16 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 17 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 18 NORTH AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 19 U.S.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 20 U.S.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 21 U.S.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 22 CANADA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 23 CANADA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 24 CANADA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 25 EUROPE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 26 EUROPE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 27 EUROPEAN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 28 EUROPE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 29 GERMANY: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 30 GERMANY: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 31 GERMANY: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 32 U.K.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 33 U.K.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 34 U.K.: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 35 FRANCE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 36 FRANCE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 37 FRANCE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 38 ROE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 39 ROE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 40 ROE: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 41 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 42 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 43 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 44 ASIA-PACIFIC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 45 JAPAN: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 46 JAPAN: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 47 JAPAN: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 48 CHINA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 49 CHINA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 50 CHINA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 51 INDIA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 52 INDIA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 53 INDIA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 54 ROAPAC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 55 ROAPAC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 56 ROAPAC: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 57 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 58 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 59 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 60 ROW: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 61 LATIN AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 62 LATIN AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 63 LATIN AMERICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 64 MIDDLE EAST: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 65 MIDDLE EAST: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 66 MIDDLE EAST: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 67 AFRICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY FUNCTIONALITY, 2012-2019 ($MILLION)
Table 68 AFRICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY DELIVERY MODE, 2012-2019 ($MILLION)
Table 69 AFRICA: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 70 TOP 5 NEW PRODUCT LAUNCHES, 2012–2014
Table 71 TOP 5 ACQUISITIONS, PARTNERSHIPS, AND AGREEMENTS, 2012–2014
Table 72 TOP 5 NEW SERVICE LAUNCHES AND SERVICE EXPANSIONS, 2012–2014
Table 73 GEOGRAPHICAL EXPANSIONS, 2012–2014
Table 74 TOP 5 OTHER DEVELOPMENTS, 2012–2014
LIST OF FIGURES
Figure 1 RESEARCH DESIGN
Figure 2 BOTTOM-UP APPROACH
Figure 3 TOP-DOWN APPROACH
Figure 4 DATA TRIANGULATION
Figure 5 ASSUMPTIONS OF THE RESEARCH STUDY
Figure 6 ADVERSE EVENT REPORTING SOFTWARE SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET OVER THE NEXT FIVE YEARS
Figure 7 NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, 2014
Figure 8 THE ON-PREMISE DELIVERY MODE SEGMENT WILL DRIVE THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET DURING 2014–2019
Figure 9 THE CROS SEGMENT ACCOUNTED FOR A MAJOR SHARE OF THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET IN 2014
Figure 10 INTENSIFICATION OF DRUG SAFETY REGULATIONS BY GOVERNMENT BODIES IS PROPELLING THE MARKET GROWTH
Figure 11 ADVERSE EVENT REPORTING SOFTWARE SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GLOBAL MARKET IN 2014
Figure 12 BUSINESS PROCESS OUTSOURCING (BPO) FIRMS TO GROW AT A HIGHER RATE DURING THE FORECAST PERIOD
Figure 13 NORTH AMERICA DOMINATES THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
Figure 14 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
Figure 15 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE
Figure 16 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
Figure 17 INCREASING DRUG SAFETY REGULATIONS TO PROPEL THE DEMAND FOR PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE
Figure 18 INTENSIFICATION OF DRUG SAFETY REGULATIONS BY GOVERNMENT AUTHORITIES DRIVING MARKET GROWTH
Figure 19 DEARTH OF SKILLS AND EXPERTISE FOR CONDUCTING CLINICAL TRIALS RESTRAINING MARKET GROWTH
Figure 20 INCREASING DEMAND FOR CLOUD TECHNOLOGY, A NEW GROWING OPPORTUNITY FOR MARKET PLAYERS
Figure 21 LACK OF STANDARDIZATION AND HARMONIZATION OF DRUG SAFETY REGULATIONS IS A KEY CHALLENGE TO THE MARKET
Figure 22 PRESENCE OF LARGE NUMBER OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IS DRIVING THE GROWTH OF THE MARKET
Figure 23 ADVERSE EVENT REPORTING SOFTWARE HOLDS LARGEST SHARE OF THE MARKET
Figure 24 ON-PREMISE DELIVERY MODE SEGMENT EXPECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE MARKET DURING 2014–2019
Figure 25 CONTRACT RESEARCH ORGANIZATIONS (CROS) COMMANDED THE LARGEST MARKET SHARE IN THE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
Figure 26 NORTH AMERICA COMMANDS LION’S SHARE OF THE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET IN 2014
Figure 27 NORTH AMERICA MARKET SNAPSHOT: DEMAND WILL BE DRIVEN BY PRESENCE OF LARGE NUMBER OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
Figure 28 EUROPE MARKET SNAPSHOT: LARGE NUMBER OF ONGOING CLINICAL TRIALS IS KEY FACTOR TO DRIVE THE MARKET GROWTH
Figure 29 ASIA-PACIFIC MARKET SNAPSHOT: INCREASING PREFERENCE OF PHARMA COMPANIES TOWARDS APAC-BASED CROS FOR CLINICAL TRIALS WILL CONTINUE TO DRIVE THE MARKET GROWTH
Figure 30 LEADING MARKET PLAYERS ADOPTED NEW PRODUCT LAUNCHES AS THEIR KEY GROWTH STRATEGY FROM 2012 TO 2014
Figure 31 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SHARE, BY KEY PLAYER, 2014
Figure 32 NEW PRODUCT LAUNCH WAS THE KEY STRATEGY
Figure 33 ORACLE CORPORATION: COMPANY SNAPSHOT
Figure 1 RESEARCH DESIGN
Figure 2 BOTTOM-UP APPROACH
Figure 3 TOP-DOWN APPROACH
Figure 4 DATA TRIANGULATION
Figure 5 ASSUMPTIONS OF THE RESEARCH STUDY
Figure 6 ADVERSE EVENT REPORTING SOFTWARE SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET OVER THE NEXT FIVE YEARS
Figure 7 NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, 2014
Figure 8 THE ON-PREMISE DELIVERY MODE SEGMENT WILL DRIVE THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET DURING 2014–2019
Figure 9 THE CROS SEGMENT ACCOUNTED FOR A MAJOR SHARE OF THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET IN 2014
Figure 10 INTENSIFICATION OF DRUG SAFETY REGULATIONS BY GOVERNMENT BODIES IS PROPELLING THE MARKET GROWTH
Figure 11 ADVERSE EVENT REPORTING SOFTWARE SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GLOBAL MARKET IN 2014
Figure 12 BUSINESS PROCESS OUTSOURCING (BPO) FIRMS TO GROW AT A HIGHER RATE DURING THE FORECAST PERIOD
Figure 13 NORTH AMERICA DOMINATES THE GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
Figure 14 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY
Figure 15 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DELIVERY MODE
Figure 16 PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER
Figure 17 INCREASING DRUG SAFETY REGULATIONS TO PROPEL THE DEMAND FOR PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE
Figure 18 INTENSIFICATION OF DRUG SAFETY REGULATIONS BY GOVERNMENT AUTHORITIES DRIVING MARKET GROWTH
Figure 19 DEARTH OF SKILLS AND EXPERTISE FOR CONDUCTING CLINICAL TRIALS RESTRAINING MARKET GROWTH
Figure 20 INCREASING DEMAND FOR CLOUD TECHNOLOGY, A NEW GROWING OPPORTUNITY FOR MARKET PLAYERS
Figure 21 LACK OF STANDARDIZATION AND HARMONIZATION OF DRUG SAFETY REGULATIONS IS A KEY CHALLENGE TO THE MARKET
Figure 22 PRESENCE OF LARGE NUMBER OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IS DRIVING THE GROWTH OF THE MARKET
Figure 23 ADVERSE EVENT REPORTING SOFTWARE HOLDS LARGEST SHARE OF THE MARKET
Figure 24 ON-PREMISE DELIVERY MODE SEGMENT EXPECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE MARKET DURING 2014–2019
Figure 25 CONTRACT RESEARCH ORGANIZATIONS (CROS) COMMANDED THE LARGEST MARKET SHARE IN THE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
Figure 26 NORTH AMERICA COMMANDS LION’S SHARE OF THE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET IN 2014
Figure 27 NORTH AMERICA MARKET SNAPSHOT: DEMAND WILL BE DRIVEN BY PRESENCE OF LARGE NUMBER OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
Figure 28 EUROPE MARKET SNAPSHOT: LARGE NUMBER OF ONGOING CLINICAL TRIALS IS KEY FACTOR TO DRIVE THE MARKET GROWTH
Figure 29 ASIA-PACIFIC MARKET SNAPSHOT: INCREASING PREFERENCE OF PHARMA COMPANIES TOWARDS APAC-BASED CROS FOR CLINICAL TRIALS WILL CONTINUE TO DRIVE THE MARKET GROWTH
Figure 30 LEADING MARKET PLAYERS ADOPTED NEW PRODUCT LAUNCHES AS THEIR KEY GROWTH STRATEGY FROM 2012 TO 2014
Figure 31 GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SHARE, BY KEY PLAYER, 2014
Figure 32 NEW PRODUCT LAUNCH WAS THE KEY STRATEGY
Figure 33 ORACLE CORPORATION: COMPANY SNAPSHOT
